Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3

NCT02057796 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

1050

Enrollment

OTHER_GOV

Sponsor class

Conditions

HIV-1 Infection

Interventions

DEVICE: Xpert MTB/RIF®, Determine TB LAM, Chest X-ray
DRUG: ART (Atripla, Truvada, Efavirenz, Combivir)
DRUG: Rifampin, isoniazid, pyrazinamide, ethambutol

Sponsor

ANRS, Emerging Infectious Diseases